Andrew Walker

Andrew Walker × George Baxter

Turning Point Brands is positioning FRE and Tucker Carlson-backed ALP as a third nicotine-pouch player, using national distribution, regulatory capability and an expanding salesforce.Cash-generative legacy businesses may support expansion, but PMTA, slotting, marketing costs and unresolved domestic-production timing and Tucker economics could pressure earnings.

Andrew Walker × Andrew Carreon

At roughly $42, Shift4 trades near 6.5x EBITDA against discussed 10–11% organic growth, making durability pivotal.Over 80% of Shift4 Dine installations reportedly come from entirely new merchants, while Global Blue and the withdrawn 2027 $1 billion exit free-cash-flow target leave 12–18 months to test synergies and credibility.

Andrew Walker × Alberto Vadia

Tiendas 3B brings Aldi/BİM’s hard-discount model to Mexico with roughly 3,700 stores, 1,000 SKUs, and over 60% private label.Organic distribution-center “cell division” supports expansion, while Vadia says halved 38% growth over two to three decades could produce a potential 100×.The key risk is whether two-year payback survives 15,000 stores as produce adds complexity and Mexico risk remains.

Andrew Walker × Yaron Naymark

Limbach’s roughly 75% peak drawdown reflects a credibility discount after EBITDA guidance fell from $90M to $80M.Yaron Naymark cites 5-6x EBITDA M&A, a clean balance sheet and Simcore’s $30M data-center entry, but H2 EBITDA growth, margin improvement and backlog economics remain to be proven against the unused $50M buyback.

Andrew Walker × Evan Vanderveer

Nubank's 140M customers and 60% Brazilian adult penetration mask Evan Vanderveer's thesis that the next five years will deepen relationships, lifting ARPAC from 17 toward the high-20s.With 20% efficiency versus 40-60% at incumbents and 7% of Brazil's $100B banking gross-profit pool, Evan underwrites $2 EPS by 2029/2030 at 16×, while credit stress, global expansion and AI commoditization remain risks.

Andrew Walker × Steve Gorelik

DNOW’s MRC Global merger creates a full-chain distributor with $75M targeted synergies and water, utilities, and data-center exposure.Buybacks at $10–12 and debt paydown support a cash-flow case, while the conservative-looking 2027 $350M EBITDA guide compares with roughly $400M on 2024 numbers.Reaching $30–32 by 2028–2029 from $16 depends on $300M 2027 FCF and re-rating, leaving ERP execution, macro recovery, and multiple expansion to monitor.

Andrew Walker × Paul Cerro

Cerro’s HIMS thesis shifts attention from peptide launches to the data and labs layer: subscriber counts have “barely grown” for three quarters, making retention the lever for LTV and payback.The August 10 print will test Eucalyptus-driven revenue upside against lower EBITDA guidance, the first full Novo Nordisk partnership quarter, and execution by management Cerro says he does not trust.

Andrew Walker × Ryan Bunn

Ryan Bunn urges CBIZ to stop buybacks, reduce leverage, and restart its historical small-deal M&A flywheel after 79 transactions over 20 years.His math contrasts roughly 8% returns before growth from buybacks plus 6.5% debt paydown with M&A's potential to double EBITDA, delever, and support a 15–16x multiple.Key watchpoints are AI disruption, the CEO's indication of no M&A in 2026, and roughly $325 million of debt to repay over 18 months.

Andrew Walker × Adam Wyden

At $7.40, Wyden frames Stagwell at roughly 4.9x 2027 EBITDA and a 22% 2027 free cash flow yield, versus $18-$26.50 under cited comparables.Large-client complexity and agency data underpin Wyden’s AI defense, while buybacks may be catalysts.Driven Brands’ Take 5 generates roughly 40% new-unit cash-on-cash returns, but debt, EV adoption and corporate costs remain unresolved risks.

Andrew Walker × EJ Karobath × Craig Larkin × Bob McGrane

MSA Safety’s shift from standalone detectors to connected hardware and MSA Plus subscription software targets 450,000 of roughly 500,000 sold devices, with Blackline’s recent take-private offering a natural experiment for the model.At $160 and roughly 20x Andrew’s $8 EPS estimate, the base case reaches $350 by 2030 on 7% growth and a 22x multiple, while the 2027–2030 J-curve, SCBA cycle and mid-single-digit guidance frame the timing risk.